Trellus Management Company’s Ligand Pharmaceuticals LGND Stock Holding History

Trellus Management Company’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,015	Closed	-$559K	–	66
2020 Q2	$559K	Hold	8,015	–	–	0.61%	35
2020 Q1	$364K	Buy	+8,015	New	+$454K	0.65%	44
2014 Q4	–	Sell	-8,523	Closed	-$250K	–	95
2014 Q3	$250K	Buy	+8,523	New	+$283K	0.21%	89
2013 Q4	–	Sell	-15,389	Closed	-$415K	–	108
2013 Q3	$415K	Buy	+15,389	New	+$433K	0.53%	64

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Trellus Management Company's LGND Position: Q3 2020 in Review

Trellus Management Company sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 8,015 shares — an estimated $559K sold.

Trellus Management Company first reported a position in LGND in Q3 2013 and held it in 4 quarters. The position peaked at $559K in Q2 2020. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

Trellus Management Company reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Trellus Management Company sold 8,015 Ligand Pharmaceuticals shares in Q3 2020, an estimated $559K.
Trellus Management Company first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 4 quarters.
Trellus Management Company's Ligand Pharmaceuticals position peaked at $559K in Q2 2020.
252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Trellus Management Company's 13F filing for Q3 2020, filed 20 Oct 2020.